¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2018 Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãß°è½ÉÆ÷Áö¾ö (MSIO Fall Conference) : 2018-10-12

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2018 Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãß°è½ÉÆ÷Áö¾ö (MSIO Fall Conference) : 2018-10-12
±³À°ÀÏÀÚ : 2018-10-12
±³À°Àå¼Ò : ÀÓÆ丮¾óÆ縮½ºÈ£ÅÚ 7Ãþ µÎº£È¦  
±³À°ÁÖÁ¦ : 2018 Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãß°è½ÉÆ÷Áö¾ö (MSIO Fall Conference)      
ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸  
´ã´çÀÚ : ½É¹Î°æ
¿¬¶ôó : 02-741-8540  
À̸ÞÀÏ : kalc@lungca.or.kr      
±³À°Á¾·ù : ³»°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 35ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í »çÀüµî·Ï ȸ¿ø: 50,000 ºñȸ¿ø 70,000 ÇöÀåµî·Ï ȸ¿ø: 60,000 ºñȸ¿ø 80,000      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 09:00~09:20 Current controversies and future perspectives in immuno-oncology biomarker testing  ±èÈ¿Áø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 09:20~09:40 Beyond PD-L1: Who will get benefit from checkpoint inhibitors?  ±èÀº°æ(BMS) 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 09:40~10:00 Genomic biomarkers for cancer immunotherapy  ½ÉÈ¿¼·(¿¬¼¼ÀÇ´ë) 
Åä·Ð 10¿ù 12ÀÏ µÎº£È¦ 10:00~10:10 Åä·Ð  () 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 10:10~10:55 Evolution of Immunotherapy Decision-Making for Non-Small Cell Lung Cancer  David R. Gandara(UC Davis Comprehensive Cancer Center) 
È޽Ġ10¿ù 12ÀÏ µÎº£È¦ 10:55~11:15 È޽Ġ () 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 11:15~11:45 Dealing with adverse events of immunotherapy : Case  ÀÓ¼±¹Î(Â÷ÀÇ°ú´ë) 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 11:45~12:15 Multiple choice questions, but one decision  ÀÌÀ±±Ô(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 12:15~13:00 Immune check point inhibitors in advanced NSCLC: Patient selection, Successes and challenges  Á¶Àº°æ(°¡ÃµÀÇ´ë) 
È޽Ġ10¿ù 12ÀÏ µÎº£È¦ 13:00~13:15 È޽Ġ () 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 13:15~14:00 Applying Advances in Genetics and Immunology to Develop Effective Immunotherapy for NSCLC Regardless of Tumor Mutational Burden  Bernard A. Fox(Earle A Chiles Research Institute Robert W. Franz Cancer Center) 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 14:00~14:20 Plasticity of innate lymphoid cells (ILCs) in tumor microenvironment  Á¤µÎÇö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 14:20~14:40 Immuno-biology of immune checkpoint receptors  ÇÏ»óÁØ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 14:40~15:00 Immunological techniques in the study of human T cells  Á¤¹Î°æ(KAIST) 
Åä·Ð 10¿ù 12ÀÏ µÎº£È¦ 15:00~15:10 Åä·Ð  () 
È޽Ġ10¿ù 12ÀÏ µÎº£È¦ 15:10~15:30 È޽Ġ () 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 15:30~15:50 Issues of Immune Checkpoint Inhiibitors as Neo-adjuvant and Adjuvnat Therapy; Surgeon's View  ±èÈ«°ü(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 15:50~16:10 Issues of Immune Checkpoint Inhibitors as Concurrent and Consolidation Therapy: Radiation Oncologist's View  ¼Û½Ã¿­(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10¿ù 12ÀÏ µÎº£È¦ 16:10~16:30 Artificial intelligence, role as a clinical decision support system  ¹Ú°Ç¿í(°è¸íÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2018 Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãß°è½ÉÆ÷Áö¾ö (MSIO Fall Conference) : 2018-10-12""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û »ï¼º¼­¿ïº´¿ø 2018 »ï¼º ¾È°ú ±Ý¿äÁý´ãȸ(¸Á¸·ÁúȯÀÇ À¯ÀüÀÚ °Ë»ç) : 2018-10-12
´ÙÀ½±Û 2018³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ °­¿øÁöȸ Áý´ãȸ : 2018-10-12
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20657 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø The 1st International Symposium on Precision Oncology in Breast Cancer : 2024-05-25 0 69 2024-05-10
20656 ¼­¿ï (¿Â¶óÀÎ)2024³â ´ëÇÑ°ñ´ë»çÇÐȸ Á¦1Â÷ FLS ÄÚµð³×ÀÌÅÍ ¿öÅ©¼ó : 2024-05-24 0 32 2024-05-10
20655 ¼­¿ï Á¦ 66ȸ Çѱ¹Ç×°ø¿ìÁÖÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-24 0 58 2024-05-10
20654 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-05-24 0 51 2024-05-10
20653 ºÎ»ê ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24 0 49 2024-05-10
20652 ¼­¿ï Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ : 2024-05-24 0 84 2024-05-10
20651 ¼­¿ï (¿Â¶óÀÎ)À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»çÁý´ãȸ-°³¿ø°¡¿¡¼­ ÀÇ·ÚµÈ ÀÌ°ú Áúȯ : 2024-05-23 0 71 2024-05-10
20650 °æ±â Çϳ²½ÃÀÇ»çȸ¿¬¼ö°­ÁÂ(¸¸¼º±âħ, ºÒ¸éÁõ) : 2024-05-23 0 82 2024-05-10
20649 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-05-23 0 53 2024-05-10
20648 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦1Â÷¿¬¼ö±³À°(ºóÇ÷ ¹× ÃâÇ÷ Áúȯ, ÀÏÂ÷ ÀÇ·á±â°ü¿¡¼­ÀÇ °ü¸®) : 2024-05-23 0 45 2024-05-10
20647 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀüÃæûÁöȸ - Á¦2Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-23 0 81 2024-05-10
20646 Á¦ÁÖ ´ëÇÑÇǺΰúÇÐȸ Á¦ÁÖÁöºÎȸ 2024³â Á¦1Â÷ Áý´ãȸ : 2024-05-22 0 30 2024-05-10
20645 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À°-¹é³»Àå ¹× Àü¾ÈºÎ ÃֽŠÁö°ß : 2024-05-21 0 75 2024-05-10
20644 ¼­¿ï ¾çõ±¸ÀÇ»çȸ Ãá°è¿¬¼ö±³À°(Á¦2Çü ´ç´¢º´°ú ¸¸¼º ½ÅÀ庴, ÀÎÁöÀå¾Ö, ¸ÞŸ¹ö½º¿Í ÀÇ·á Çõ¸í) : 2024-05-21 0 72 2024-05-10
20643 ÃæºÏ 2024 Á¦Ãµ½ÃÀÇ»çȸ Ãá°è ¿¬¼ö°­Á : 2024-05-21 0 14 2024-05-10
31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷